Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BML-190 (Indomethacin morpholinylamide) 是一种 CB2 受体的配体,其对 CB2 受体 (Ki:435 nM) 和 CB1受体 (Ki< 2 μM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 167 | 现货 | ||
10 mg | ¥ 297 | 现货 | ||
25 mg | ¥ 553 | 现货 | ||
50 mg | ¥ 990 | 现货 | ||
100 mg | ¥ 1,720 | 现货 | ||
200 mg | ¥ 2,560 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 167 | 现货 |
产品描述 | BML-190 (Indomethacin morpholinylamide) is a specific CB2 receptor inverse agonist (Ki: 435 nM), with 50-fold selectivity over CB1 receptor. |
靶点活性 | CB2:435 nM(Ki) |
体外活性 | BML-190 has 50-fold selectivity for CB2 receptors over CB1 receptors. In HEK-293 cells stably expressing the human CB2 receptor, BML-190 potentiates the forskolin-stimulated accumulation of cAMP. BML-190 reduces the basal levels of inositol phosphate production in cells expressing the CB2 receptor. 10 μM of BML-190 decreases inositol phosphates accumulation by 38%. [1] BML-190 is an aminoalkylindole. BML-190 is found to yield at least 15 metabolic products. [2] BML-190 diminishes LPS-induced NO and IL-6 production in a concentration-dependent manner. BML-190 also inhibits LPS-induced PGE2 production and COX-2 induction. [3] |
细胞实验 | 293/CB2 cells are labeled with [3H]adenine (1 μCi/mL) in MEM with 1% FBS for 20 hours-24 hours. Labelled cells are challenged with 50 μM forskolin and appropriate BML-190 for 30 minutes at 37°C and assayed for cAMP accumulation. For IP assays, 2 × 105 293/CB2 cells are transiently transfected with 16z44 and/or pcDNA3 using transfection reagents. Cells are labelled, challenged with BML-190 and assayed for IP production. Triplicates are performed for each data point and at least three separate trials are done for each ligand.(Only for Reference) |
别名 | 2-[1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1H-吲哚-3-基]-1-(4-吗啉基)乙酮, Indomethacin morpholinylamide, 吲哚美辛吗啉代酰胺, IMMA, BML 190 |
分子量 | 426.89 |
分子式 | C23H23ClN2O4 |
CAS No. | 2854-32-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 21 mg/mL (49.2 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3425 mL | 11.7126 mL | 23.4252 mL | 58.5631 mL |
5 mM | 0.4685 mL | 2.3425 mL | 4.685 mL | 11.7126 mL | |
10 mM | 0.2343 mL | 1.1713 mL | 2.3425 mL | 5.8563 mL | |
20 mM | 0.1171 mL | 0.5856 mL | 1.1713 mL | 2.9282 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BML-190 2854-32-2 GPCR/G Protein Cannabinoid Receptor inhibit 2-[1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1H-吲哚-3-基]-1-(4-吗啉基)乙酮 Inhibitor Indomethacin morpholinylamide 吲哚美辛吗啉代酰胺 IMMA BML190 BML 190 inhibitor